Current Opinion in Virology

Papers
(The median citation count of Current Opinion in Virology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Structure of SARS-CoV-2 spike protein150
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19128
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection106
Current challenges to virus discovery by meta-transcriptomics68
Future considerations for the mRNA-lipid nanoparticle vaccine platform66
Zoonotic disease and virome diversity in bats63
Global overview and major challenges of host prediction methods for uncultivated phages62
Structure and function of SARS-CoV-2 polymerase57
The virome of vector mosquitoes57
Coronavirus entry: how we arrived at SARS-CoV-257
A structural view of the SARS-CoV-2 virus and its assembly55
RNA viruses and the cGAS-STING pathway: reframing our understanding of innate immune sensing55
Animal models for SARS-CoV-254
The healthy human virome: from virus–host symbiosis to disease51
Engineering therapeutic phages for enhanced antibacterial efficacy50
Structure, function and assembly of the long, flexible tail of siphophages46
Recent advances in understanding plant antiviral RNAi and viral suppressors of RNAi46
Viral Z-RNA triggers ZBP1-dependent cell death44
Cell-to-cell movement of plant viruses via plasmodesmata: a current perspective on potyviruses44
European regulatory aspects of phage therapy: magistral phage preparations40
COVID-19, the first pandemic in the post-genomic era40
Anti-viral protective capacity of tissue resident memory T cells40
Perspective on taxonomic classification of uncultivated viruses38
Host cell-intrinsic innate immune recognition of SARS-CoV-237
Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?37
Entry of influenza A virus into host cells — recent progress and remaining challenges36
Tombusviruses orchestrate the host endomembrane system to create elaborate membranous replication organelles35
Mitigation of evolved bacterial resistance to phage therapy34
Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world32
Viral structural proteins as targets for antivirals32
Detection of viruses by inflammasomes31
Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy30
Rotavirus cell entry: not so simple after all30
Current view and perspectives in viroid replication30
Hepatitis B virus–host interactions and novel targets for viral cure29
Drug resistance mutations in HIV: new bioinformatics approaches and challenges29
Adenovirus – a blueprint for gene delivery29
Epigenetic control of the Epstein-Barr lifecycle28
Digital phagograms: predicting phage infectivity through a multilayer machine learning approach28
Measles immunity and immunosuppression28
Animal models of SARS-CoV-2 transmission28
Immune system control of hepatitis C virus infection27
Natural killer cells and unconventional T cells in COVID-1926
An overview of the current state of phage therapy for the treatment of biofilm-related infections26
Progress and pitfalls of a year of drug repurposing screens against COVID-1925
Molecular dynamics of the viral life cycle: progress and prospects25
The gut virome in inflammatory bowel diseases24
Targeting of viral RNAs by Upf1-mediated RNA decay pathways23
The long and winding road: human papillomavirus entry and subcellular trafficking23
Development of plant-made monoclonal antibodies against viral infections23
Proteases and variants: context matters for SARS-CoV-2 entry assays23
R gene mediated defense against viruses23
Remdesivir for the treatment of Covid-19: the value of biochemical studies22
Revisiting an old friend: new findings in alphavirus structure and assembly22
Mapping the diverse structural landscape of the flavivirus antibody repertoire22
UPR signaling at the nexus of plant viral, bacterial, and fungal defenses22
Antiviral immunity triggered by infection-induced host transposable elements21
Broadly neutralizing antibodies against HIV-1 and concepts for application21
Evolution of the interferon response: lessons from ISGs of diverse mammals21
Principles of epithelial homeostasis control during persistent human papillomavirus infection and its deregulation at the cervical transformation zone21
Tissues: the unexplored frontier of antibody mediated immunity21
Assembly of the virome in newborn human infants20
Human genetic and immunological dissection of papillomavirus-driven diseases: new insights into their pathogenesis20
The enigmatic roles of Anelloviridae and Redondoviridae in humans20
Phage therapy for secondary bacterial infections with COVID-1920
Unresolved questions in the zoonotic transmission of MERS20
Virus genomics: what is being overlooked?19
Shopping for phages? Unpacking design rules for therapeutic phage cocktails19
The origin of Human Papillomavirus (HPV) — induced cervical squamous cancer18
The influence of microbiota-derived metabolites on viral infections18
Endocytosis of Bacteriophages18
Cryo-electron microscopy of nodavirus RNA replication organelles illuminates positive-strand RNA virus genome replication18
The surface glycoproteins of hantaviruses18
Advances in human monoclonal antibody therapy for HBV infection18
Bat virome research: the past, the present and the future17
Flavivirus nonstructural proteins and replication complexes as antiviral drug targets16
Antigenic evolution of SARS coronavirus 216
Fruit bats as natural reservoir of highly pathogenic henipaviruses: balance between antiviral defense and viral tolerance16
Innate immunity and HBV persistence16
Structures of the tailed bacteriophages that infect Gram-positive bacteria16
Immunotherapy and therapeutic vaccines for chronic HBV infection16
Immune–bacteriophage interactions in inflammatory bowel diseases16
Microbiota as a potentially-modifiable factor influencing COVID-1915
Virus–host protein interactions as footprints of human cytomegalovirus replication15
Emerging technologies in the study of the virome15
Bioinformatics of virus taxonomy: foundations and tools for developing sequence-based hierarchical classification15
The remarkable viral portal vertex: structure and a plausible model for mechanism15
Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination15
Progress and prospects of the healthy human gut virome14
Broadly neutralizing antibodies against COVID-1914
Virion structures and genome delivery of honeybee viruses14
Fighting viruses with computers, right now14
The enigma of picobirnaviruses: viruses of animals, fungi, or bacteria?13
SARS-CoV-2 vaccines — the biggest medical research project of the 21st century13
Seeing and touching adenovirus: complementary approaches for understanding assembly and disassembly of a complex virion13
Immunodominance complexity: lessons yet to be learned from dominant T cell responses to SARS-COV-213
Teaching old dogmas new tricks: recent insights into the nuclear import of HIV-113
Mutational escape from cellular immunity in viral hepatitis: variations on a theme13
Co-opted membranes, lipids, and host proteins: what have we learned from tombusviruses?13
The journey of herpesvirus capsids and genomes to the host cell nucleus13
Viral–host interactions during splicing and nuclear export of influenza virus mRNAs13
Hepatitis B virus e antigen and viral persistence12
Fishing for phages in metagenomes: what do we catch, what do we miss?12
Cytotoxicity in Epstein Barr virus specific immune control12
Quantitative measures of within-host viral genetic diversity12
HIV persistence: silence or resistance?12
Arms race between rice and viruses: a review of viral and host factors12
The road to effective and accessible antibody therapies against Ebola virus11
Hepatitis C virus and intracellular antiviral response11
Structural perspectives on HCV humoral immune evasion mechanisms11
SnRK1: a versatile plant protein kinase that limits geminivirus infection11
Understanding T cell aging to improve anti-viral immunity11
Structural and dynamic asymmetry in icosahedrally symmetric virus capsids10
The biology of papillomavirus PDZ associations: what do they offer papillomaviruses?10
Plant negative-stranded RNA virus biology and host interactions revitalized by reverse genetics10
Platelets in the pathogenesis of flavivirus disease10
Structure and physiology of giant DNA viruses10
Time to ‘Mind the Gap’ in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-210
The morphogenesis of different giant viruses as additional evidence for a common origin of Nucleocytoviricota10
Mapping conformational epitopes by NMR spectroscopy10
Recent progress in development of monoclonal antibodies against human cytomegalovirus10
T cell responses during HBV and HCV infections: similar but not quite the same?10
The importance of viral and cellular factors on flavivirus entry9
The female reproductive tract virome: understanding the dynamic role of viruses in gynecological health and disease9
Virus structure and structure-based antivirals9
Broad neutralizing antibody-based strategies to tackle influenza9
Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy9
Immunity to acute virus infections with advanced age9
Know your enemy and know yourself – the case of SARS-CoV-2 host factors9
Therapeutic approaches to Epstein–Barr virus cancers9
Gut virome in early life: origins and implications9
Host defence and persistent human papillomavirus infection9
Non-structural protein 5 (NS5) as a target for antiviral development against established and emergent flaviviruses9
Flavivirus–host interactions: an expanding network of proviral and antiviral factors9
Hepatitis C virus envelope protein dynamics and the link to hypervariable region 19
HIV-1 entry: Duels between Env and host antiviral transmembrane proteins on the surface of virus particles9
Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity9
Deimmunization of flagellin adjuvant for clinical application9
0.032512903213501